Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

Med Mycol. 2019 Apr 1;57(Supplement_2):S127-S137. doi: 10.1093/mmy/myy091.

Abstract

In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

Keywords: acute myeloid leukemia; antifungal prophylaxis; breakthrough fungal infections; triazoles.

Publication types

  • Consensus Development Conference

MeSH terms

  • Antifungal Agents / administration & dosage*
  • Chemoprevention / methods*
  • Disease Management*
  • Humans
  • Invasive Fungal Infections / diagnosis
  • Invasive Fungal Infections / drug therapy
  • Invasive Fungal Infections / epidemiology*
  • Invasive Fungal Infections / prevention & control*
  • Italy / epidemiology
  • Leukemia, Myeloid, Acute / complications*
  • Triazoles / administration & dosage*

Substances

  • Antifungal Agents
  • Triazoles